The Goal of the SystHERs Registry
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Clinical Pearls:
- This registry will enroll patients who have been diagnosed with HER2/neu-positive metastatic breast cancer within the last 6 months.
- The registry will collect detailed information on patients who are diagnosed with HER2 metastatic breast cancer to look both at the demographic factors as well as their past history.
- The registry will also look at what treatment they receive in the metastatic setting, what their outcomes are in terms of response and side effects.
- This will help researchers better understand how patients react to new agents that have been developed in this space.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
